Wedbush Reiterates “Outperform” Rating for Voyager Therapeutics (NASDAQ:VYGR)

Voyager Therapeutics (NASDAQ:VYGR)‘s stock had its “outperform” rating reissued by equities researchers at Wedbush in a research note issued on Wednesday,Benzinga reports.

A number of other brokerages have also weighed in on VYGR. Canaccord Genuity Group reiterated a “buy” rating and set a $14.00 price objective on shares of Voyager Therapeutics in a report on Thursday, November 14th. Cantor Fitzgerald reissued an “overweight” rating on shares of Voyager Therapeutics in a research report on Wednesday. Citigroup initiated coverage on shares of Voyager Therapeutics in a research report on Monday, December 2nd. They set a “buy” rating and a $12.00 target price on the stock. StockNews.com downgraded shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Finally, HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of Voyager Therapeutics in a research report on Monday, March 3rd. One investment analyst has rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $14.86.

Voyager Therapeutics Price Performance

Shares of VYGR opened at $4.07 on Wednesday. Voyager Therapeutics has a 1-year low of $3.56 and a 1-year high of $10.66. The company has a 50-day moving average of $4.91 and a 200 day moving average of $5.86. The firm has a market capitalization of $222.33 million, a price-to-earnings ratio of 5.73 and a beta of 0.99.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings data on Tuesday, March 11th. The company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.24). Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The company had revenue of $4.39 million for the quarter, compared to the consensus estimate of $16.58 million. During the same quarter in the previous year, the business earned $1.25 EPS. On average, equities analysts anticipate that Voyager Therapeutics will post -0.91 earnings per share for the current fiscal year.

Insider Transactions at Voyager Therapeutics

In other Voyager Therapeutics news, COO Robin Swartz sold 6,500 shares of the business’s stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $5.65, for a total transaction of $36,725.00. Following the sale, the chief operating officer now owns 112,328 shares of the company’s stock, valued at approximately $634,653.20. The trade was a 5.47 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 10,778 shares of company stock valued at $58,548 in the last 90 days. Insiders own 4.53% of the company’s stock.

Institutional Trading of Voyager Therapeutics

Several large investors have recently bought and sold shares of VYGR. Cubist Systematic Strategies LLC purchased a new stake in Voyager Therapeutics during the 4th quarter worth approximately $29,000. Tower Research Capital LLC TRC grew its position in Voyager Therapeutics by 133.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company’s stock worth $31,000 after purchasing an additional 3,077 shares during the last quarter. Picton Mahoney Asset Management grew its position in Voyager Therapeutics by 71.1% during the 4th quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company’s stock worth $33,000 after purchasing an additional 2,444 shares during the last quarter. Oxford Asset Management LLP acquired a new stake in Voyager Therapeutics during the 4th quarter valued at approximately $60,000. Finally, Intech Investment Management LLC acquired a new stake in Voyager Therapeutics during the 3rd quarter valued at approximately $74,000. Hedge funds and other institutional investors own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.